Skip to content
Triangle logo TriangleGet started
← Full study record

NCT00072514 · OUTCOME

Peripheral Blood Stem Cell Collection

Gemcitabine Hydrochloride, Carboplatin, Dexamethasone, and Rituximab in Treating Patients With Previously Treated Lymphoid Malignancies · Source last updated 2017-06-29

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

Measure
COUNT_OF_PARTICIPANTS
Unit
Participants
Interval / dispersion
Not reported
Time frame
Up to 12 weeks

What was measured

Count of patients that attempted and had successful autologous peripheral blood stem cell (PBSC) collection.

Analysis population: Successful PBSC collection is only considered in those patients that attempted PBSC collection.

Groups in this outcome

Treatment

Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.

Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.

Analysis denominator · Participants

GroupSource count
Treatment51

Reported measurements

Attempted PBSC Collection

Analysis denominator · Participants

GroupSource count
Treatment51
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment17Not reportedNot reportedNot reportedNot reported
Successful PBSC Collection

Analysis denominator · Participants

GroupSource count
Treatment17
Values in Participants · Interval/dispersion: Not reported
GroupValueSpreadLowerUpperComment
Treatment17Not reportedNot reportedNot reportedNot reported
Complete source fields
classes
  1. categories
    1. measurements
      1. group Id
        OG000
        value
        17
    denoms
    1. counts
      1. group Id
        OG000
        value
        51
      units
      Participants
    title
    Attempted PBSC Collection
  2. categories
    1. measurements
      1. group Id
        OG000
        value
        17
    denoms
    1. counts
      1. group Id
        OG000
        value
        17
      units
      Participants
    title
    Successful PBSC Collection
denoms
  1. counts
    1. group Id
      OG000
      value
      51
    units
    Participants
description
Count of patients that attempted and had successful autologous peripheral blood stem cell (PBSC) collection.
groups
  1. description
    Patients receive gemcitabine hydrochloride intravenously (IV) over 30 minutes on days 1 and 8, carboplatin IV over 30-60 minutes on day 1, and dexamethasone orally (PO) on days 1-4. Treatment repeats every 21 days for up to 4 courses in the absence of disease progression or unacceptable toxicity. Patients with CD20-POSITIVE LYMPHOMAS also receive rituximab IV on day 8.
    id
    OG000
    title
    Treatment
param Type
COUNT_OF_PARTICIPANTS
population Description
Successful PBSC collection is only considered in those patients that attempted PBSC collection.
reporting Status
POSTED
time Frame
Up to 12 weeks
title
Peripheral Blood Stem Cell Collection
type
SECONDARY
unit Of Measure
Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice